High-risk follicular lymphoma patients: identification and treatment

High-risk follicular lymphoma patients: identification and treatment

Authors

  • Stefano Luminari Hematology Unit, Azienda Unità Sanitaria Locale – IRCCS Reggio Emilia, Italy and Department of Diagnostic, Clinical and Public Health Medicine, University of Modena and Reggio Emilia, Reggio Emilia, Italy
  • Francesco Merli Hematology Unit, Azienda Unità Sanitaria Locale – IRCCS Reggio Emilia, Italy

Keywords:

Follicular Lymphoma, Prognosis, Prognostic factors, High risk, early progression,

Abstract

Over the last 15 years, the outcome of patients with follicular lymphoma (FL) has dramatically improved mainly as a result of effective therapies and of a better understanding of lymphoma biology. Although progression-free survival is approximately 10 years with standard treatment and overall survival upwards of 20 years, the clinical behavior among individual patients is highly heterogenous, and a significant number of subjects have a higher and earlier risk of dying from FL within a few years from diagnosis. In this article, we provide an overview of available prognostic tools that can be used to identify high-risk patients with FL and describe which therapies are available and can be recommended for this group of hard-to-treat FL patients.

Downloads

Published

2018-07-31

How to Cite

1.
Luminari S, Merli F. High-risk follicular lymphoma patients: identification and treatment. Eur J Oncol Env Hea [Internet]. 2018 Jul. 31 [cited 2025 Apr. 6];23(1):19-2. Available from: https://mattioli1885journals.com/index.php/EJOEH/article/view/7339